EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of Empagliflozin Treatment on Ventricular Repolarization Parameters

Fatih Ozturk, Hasim Tuner, Adem Atici, Hasan Ali Barman

Reviews in Cardiovascular Medicine · 18.02.2024 · 25 (2)

DOI: 10.31083/j.rcm2502064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 18.02.2024. Verfasst von Fatih Ozturk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Yuzuncu yil University, Faculty of Medicine, 65080 Van, Turkey. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

An example of a sodium-glucose cotransporter-2 (SGLT-2) inhibitor is Empagliflozin. It is a new medicine for treating type 2 diabetes mellitus (T2DM), but there is increasing interest in how empagliflozin affects the heart. This study aims to examine the impact of empagliflozin treatment on ventricular repolarization parameters in T2DM patients.

Methods

T2DM patients were included in a prospective study. Measurements of ventricular repolarization parameters, including QT interval, corrected QT interval (QTc), QT dispersion (QTd), Tpeak-to-Tend interval (Tp-e), and Tpeak-to-Tend interval corrected for QTc (Tp-e/QTc), were obtained before initiating empagliflozin treatment and six months following treatment initiation. Statistical analysis was performed to assess changes in these parameters.

Results

In this study, 95 patients were diagnosed with T2DM out of 177 patients. Among T2DM patients, 40 were male (42%) compared to 48% males in controls (p = 0.152). The average age of the T2DM patients was 60.2 ± 9.0 years, compared to 58.2 ± 9.2 years in the control group (p = 0.374). When comparing pre- and post-treatment measurements of parameters representing ventricular repolarization (QT 408.5 ± 22.9/378.8 ± 14.1, p < 0.001; QTc 427.0 ± 20.5/404.7 ± 13.8, p < 0.001; QTd 52.1 ± 1.2/47.8 ± 1.7, p < 0.001; Tp-e 82.3 ± 8.7/67.1 ± 5.1, p < 0.001; Tp-e/QTc 0.19 ± 0.01/0.17 ± 0.01, p < 0.001 (respectively)), statistically significant improvements were observed. A statistically significant dose-dependent decline in the magnitude of change in the QTc parameter (19.4/29.6, p = 0.038) was also observed.

Conclusions

According to these results, empagliflozin may decrease the risk of potential ventricular arrhythmias.

Schlagwörter

Stichwörter der Autor:innen

QT intervalSGLT-2 inhibitorarrhythmiasempagliflozintype 2 diabetes mellitusventricular repolarization

Autor:innen und Institutionen

  • Department of Cardiology, Yuzuncu yil University, Faculty of Medicine, 65080 Van, Turkey.
  • Department of Cardiology, Istanbul Medeniyet University, Faculty of Medicine, Goztepe Training and Research Hospital, 34722 Istanbul, Turkey.
  • Department of Cardiology, Istanbul University - Cerrahpaşa, Institute of Cardiology, 34390 Istanbul,Turkey.

Zitieren

APA

Ozturk, F., Tuner, H., Atici, A., & Ali Barman, H. (2024). Effect of Empagliflozin Treatment on Ventricular Repolarization Parameters. Reviews in Cardiovascular Medicine, 25(2). https://doi.org/10.31083/j.rcm2502064

Vancouver

Ozturk F, Tuner H, Atici A, Ali Barman H. Effect of Empagliflozin Treatment on Ventricular Repolarization Parameters. Reviews in Cardiovascular Medicine. 2024;25(2). doi:10.31083/j.rcm2502064

BibTeX
@article{Ozturk2024,
  author = {Ozturk, Fatih and Tuner, Hasim and Atici, Adem and Ali Barman, Hasan},
  title = {Effect of Empagliflozin Treatment on Ventricular Repolarization Parameters},
  journal = {Reviews in Cardiovascular Medicine},
  year = {2024},
  volume = {25},
  number = {2},
  doi = {10.31083/j.rcm2502064}
}
Kostenlos starten →